First Trust Advisors LP Contrafect Corp Transaction History

First Trust Advisors LP

  • $101 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$3.19 - $4.43 $277,150 - $384,882
-86,881 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$3.58 - $4.9 $83,192 - $113,866
23,238 Added 36.51%
86,881 $382,000
Q1 2021

May 14, 2021
BUY
$4.46 - $6.68 $22,777 - $34,114
5,107 Added 8.72%
63,643 $305,000
Q4 2020

Feb 02, 2021
SELL
$5.05 - $6.4 $13,352 - $16,921
-2,644 Reduced 4.32%
58,536 $296,000
Q3 2020

Nov 05, 2020
BUY
$5.05 - $6.99 $308,959 - $427,648
61,180 New
61,180 $323,000

Others Institutions Holding CFRX

# of Institutions
2
Shares Held
49.2K
Call Options Held
0
Put Options Held
0
View Full List

About CONTRAFECT Corp

CFRX Quotes by TradingView
  • Ticker CFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,332,700
  • Market Cap $1.18M
  • Description
  • ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...
More about CFRX
Track This Portfolio

Track First Trust Advisors LP Portfolio

Follow First Trust Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email